EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia

Journal article

Peer reviewed

F Sanai, M Aljawad, A S Alghamdi, A Khathlan, M Alghamdi, S Kozma, N Smith, F El Moustaid, S Jeyakumar and N Kachru

Value in health, Vol.25(12), pp.S171-S172

12/2022

Metrics

1 Record Views

Title: EE592 Long-Term Health and Economic Benefits of Switching to Tenofovir Alafenamide Versus Continuing on Entecavir in Chronic Hepatitis B Patients With Low-Level Viremia in Saudi Arabia
Creators - without role: F Sanai - King Abdulaziz Medical City
M Aljawad - King Fahad Specialist Hospital
A S Alghamdi - King Fahad Hospital Jeddah
A Khathlan - King Fahd Medical City
M Alghamdi - King Fahd Military Medical Complex
S Kozma - 6Gilead Sciences, Inc, Dubai, United Arab Emirates
N Smith - Product Innovation and Engineering (United States, Saint James) - LLC
F El Moustaid - Product Innovation and Engineering (United States, Saint James) - LLC
S Jeyakumar - Product Innovation and Engineering (United States, Saint James) - LLC
N Kachru - Gilead Sciences
Publication Details: Value in health, Vol.25(12), pp.S171-S172
Publisher: Elsevier Inc
Identifiers: 9921995708331
Language: English
Resource Type: Journal article